FDA clears Dexcom Stelo OTC

Continuous glucose monitors used to sit firmly inside the medical system. You got one because a clinician prescribed it, usually for diabetes management, an(fda.gov)xcom’s Stelo as the first over-the-counter continuous glucose monitor in the U.S. for adults who do not use insulin. (fda.gov)exactly? Stelo is a wearable glucose sensor from Dexcom — basically a simpler consumer-facing version of the company’s CGM tec(fda.gov)tead of giving you a one-off fingerstick number. The app shows trends and patterns, not just isolated readings. (fda.gov) ### Who is it actually for? This is the key distinction. Stelo is intended for people 18 and older who are not on insulin. That includes some people with Type 2 diabetes (fda.gov)ose. Dexcom pitches it as a tool for understanding patterns and building habits, not as a replacement for intensive diabetes management. (fda.gov) ### Why is over-the-counter status a big deal? Because prescription requirements were doing more than screening for safe(fda.gov) diabetes without insulin use, getting a CGM often meant a doctor visit, paperwork, and maybe no coverage anyway. OTC clearance turns that into a retail purchase. The FDA framed that as a health-equity move because it lets people buy the device without needing a prescriber or insurance gatekeeper. (fda.gov) ### What(fda.gov)esigned to be worn for up to 15 days before replacement. Dexcom’s current sales page shows a one-time purchase of two biosensors for $99, which works out to about a month of wear if both sensors last their full cycle. The device is also sold through subscriptions. (fda.gov) ### What’s the catch? The catch is that this is not for everyone. The FDA says Stelo is not for people with problematic hypoglycemia because it is not des(fda.gov)o the product widens access, but it does that by narrowing the use case to lower-risk consumers. (fda.gov) ### Does this mean CGMs are becoming wellness devices? Partly, yes. But “wellness” undersells what is happening. Stelo sits in a new middle category — more serious than a fitne(fda.gov), exercise, and stress feedback, which makes the product feel consumer-first. But the underlying device is still regulated glucose-sensing hardware, and the FDA reviewed clinical data showing performance similar to other integrated CGMs. (fda.gov) ### Why does (fda.gov)s, for digital health apps, and for the idea that people might run short glucose-tracking experiments the way they already run step-count or sleep experiments. Dexcom launched Stelo for sale on August 26, 2024, after the March clearance, which turned the FDA decision from a regulatory first into an actual consumer market. (investors.dexcom.com) ### Bottom line? Stelo matters (fda.gov) to real metabolic data. But the boundaries matter just as much: this is a pattern-tracking tool for non-insulin users, not a universal diabetes device. (fda.gov)